MicroRNA-203 Modulates the Radiation Sensitivity of Human Malignant Glioma Cells.
Seoul, South Korea. In Int J Radiat Oncol Biol Phys, Nov 2015
Western blot analysis validated the fact that miR-203 downregulated ATM, RAD51, SRC, PLD2, PI3K-AKT, JAK-STAT3, VEGF, HIF-1α, and MMP2.
Syntenin and syndecan in the biogenesis of exosomes.
Marseille, France. In Biol Cell, Oct 2015
SDC-syntenin-associated regulators include the endosomal sorting complex required for transport accessory component ALG-2-interacting protein X, the small GTPase adenosine 5'-diphosphate-ribosylation factor 6, the lipid-modifying enzyme phospholipase D2 and the endoglycosidase heparanase.
The phospholipase D superfamily as therapeutic targets.
Stony Brook, United States. In Trends Pharmacol Sci, Mar 2015
With the advent of loss-of-function genetic mouse models that have revealed that PLD1 and PLD2 ablation is overtly tolerable, small-molecule PLD1/2 inhibitors that do not cause unacceptable clinical toxicity, a PLD2 polymorphism that has been linked to altered physiology, and growing delineation of processes that are subtly altered in mice lacking PLD1/2 activity, the stage is being set for assessment of PLD1/2 inhibition for therapeutic purposes.
Phospholipase D in cell signaling: from a myriad of cell functions to cancer growth and metastasis.
Dayton, United States. In J Biol Chem, 2014
The particular involvement of PLD in cell migration is accomplished: (a) through the actions of its enzymatic product of reaction, phosphatidic acid, and its unique shape-binding role on membrane geometry; (b) through a particular guanine nucleotide exchange factor (GEF) activity (the first of its class assigned to a phospholipase) in the case of the mammalian isoform PLD2; and (c) through protein-protein interactions with a wide network of molecules: Wiskott-Aldrich syndrome protein (WASp), Grb2, ribosomal S6 kinase (S6K), and Rac2.
A new role for cyclic phosphatidic acid as a PPARgamma antagonist.
San Diego, United States. In Cell Metab, 2010
A recent study in Molecular Cell (Tsukahara et al., 2010) identifies cyclic phosphatidic acid (CPA) as a naturally occurring PPARgamma antagonist that can be generated from lysophospholipids by signal-dependent activation of phospholipase D2.